← Patent-cliff monitor small molecule REXULTI BREXPIPRAZOLE
Loss of exclusivity April 2033 latest FDA-listed patent expiry
Drug detail Brand name REXULTI Active ingredient BREXPIPRAZOLE Strength 0.25MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval July 2015 Marketing status RX
Listed patents Patent Expires Type 10307419*PED April 2033 — 10307419 October 2032 product RE48059*PED June 2029 — RE48059 December 2028 substance 9839637*PED October 2026 — 8618109*PED October 2026 — 7888362*PED October 2026 — 8349840*PED October 2026 — 8349840 April 2026 product 7888362 April 2026 substance 9839637 April 2026 product 8618109 April 2026 use U-3281
Regulatory exclusivity Code Expires M-315 May 2028 PED November 2027 M-14 May 2027 PED November 2026 I-913 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.